CytomX Therapeutics announced clinical trial updates regarding its candidates, including CX-2051 for colorectal cancer and CX-801 for metastatic melanoma.

1 report, 1 independent Updated Aug 8

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

CytomX Therapeutics (United States)

Keep exploring

Part of

CytomX Therapeutics developed therapeutic candidates, including Antibody-Drug Conjugates (ADCs). All 1 developments

The entities involved

CytomX Therapeutics (United States)
company in South San Francisco, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 8GuruFocus.comCytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... Cash and Investments: $158.1 million as of June 30, 2025. Revenue: $18.7 million for Q2 2025, compared to